Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14791.203 | 0.4978 | 0.2901 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14791.203 | 0.4978 | 0.2901 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14791.203 | 0.3029 | -0.0560 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14791.203 | 0.3029 | -0.0560 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14791.203 | 0.0426 | -0.7249 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14791.203 | 0.0426 | -0.7249 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14791.203 | 0.0134 | -0.8671 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14791.203 | 0.0134 | -0.8671 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14791.203 | 0.0131 | -0.8691 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14791.203 | 0.0131 | -0.8691 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 15315.203 | 0.9788 | 0.9666 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 15315.203 | 0.9788 | 0.9666 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 15315.203 | 0.9257 | 0.8825 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 15315.203 | 0.9257 | 0.8825 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 15315.203 | 0.9862 | 0.9783 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 15315.203 | 0.9862 | 0.9783 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 15315.203 | 0.7314 | 0.5653 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 15315.203 | 0.7314 | 0.5653 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 15315.203 | 0.4746 | 0.1153 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 15315.203 | 0.4746 | 0.1153 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 15315.203 | 0.3746 | -0.0733 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 15315.203 | 0.3746 | -0.0733 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 15315.203 | 0.1638 | -0.5155 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 15315.203 | 0.1638 | -0.5155 | 1.2762 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 15315.203 | 0.0906 | -0.6954 | 1.2762 |